DILANTIN

Compare DILANTIN  to:
Compare
Compare

Generic Name for DILANTIN

Phenytoin sodium 30mg, 100mg; ext-rel caps.

Legal Classification:

Rx

Pharmacological Class for DILANTIN

Hydantoin.

Manufacturer of DILANTIN

Pfizer Labs

Indications for DILANTIN

Tonic-clonic, psychomotor and neurosurgically induced seizures.

Adult dose for DILANTIN

Initially: 100mg 3 times daily. Increase weekly if needed; max 200mg 3 times daily. Once-a-day dosing only with ext-rel caps for patients controlled on 300mg daily.

Children's dosing for DILANTIN

Initially 5mg/kg per day in 2–3 equally divided doses. Increase weekly if needed. Usual maintenance: 4–8mg/kg per day; max 300mg daily.

Also:

Precautions for DILANTIN

Diabetes. Impaired liver function. Change dose gradually. Discontinue if rash develops. Monitor serum levels. Use proper dental hygiene. Hormonal contraception. Porphyria. Elderly. Debilitated. Pregnancy. Nursing mothers: not recommended.

Interactions for DILANTIN

Potentiated by acute alcohol ingestion, amiodarone, benzodiazepines (eg, diazepam), chloramphenicol, dicumarol, disulfiram, estrogens, fluoxetine, halothane, H2 blockers, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinamides (eg, ethosuximide), sulfonamides, tolbutamide, trazodone, others. Antagonized by chronic alcohol ingestion, carbamazepine, reserpine, others. Antagonizes tricyclic antidepressants, oral anticoagulants, oral contraceptives, estrogens, corticosteroids, doxycycline, digitoxin, furosemide, theophylline, rifampin, quinidine, vitamins D and K, others. Variable effects with phenobarbital, valproic acid, divalproex, others. Absorption decreased by calcium, antacids.

Adverse Reactions for DILANTIN

Nystagmus, ataxia, slurred speech, decreased coordination, dizziness, GI disturbances, gingival hyperplasia, osteomalacia, blood dyscrasias, lymphadenopathy, hepatic disease, rash, hyperglycemia, SLE, hypertrichosis.

How is DILANTIN supplied?

Caps, Tabs—100
Susp—8oz

Related Disease:

Epilepsy
Seizure disorders

Related Resources

Lamictal XR approved as add-on therapy for primary generalized tonic-clonic seizures

February 01, 2010

The FDA has approved Lamictal XR (lamotrigine extended-release tablets, from GlaxoSmithKline) as a once daily, add-on therapy for epilepsy in patients ≥13 years of age with primary generalized tonic-clonic seizures.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

FDA accepts NDA for retigabine, a treatment for partial-onset seizures

January 04, 2010

Valeant has announced that the FDA has accepted for review the New Drug Application (NDA) for retigabine, a neuronal potassium channel opener for the adjunctive treatment for adult epilepsy patients with partial-onset seizures.

FDA warns of birth defects with valproate sodium, valproic acid, and divalproex sodium

December 03, 2009

The FDA has notified healthcare professionals and patients about the increased risk of neural tube defects and other major birth defects (eg, craniofacial defects and cardiovascular malformations) in babies exposed to valproate sodium and related products (valproic acid and divalproex sodium) during pregnancy.

Sabril available for infantile spasms and adult epileptic seizures

September 21, 2009

Lundbeck has made available Sabril (vigabatrin) powder for oral solution and tablets for the treatment of infantile spasms and refractory complex partial seizures.